Zheng-Rong Shi
Overview
Explore the profile of Zheng-Rong Shi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
50
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Chen K, Feng X, Shi Y, Li X, Shi Z, Lan X
World J Gastrointest Oncol
. 2025 Jan;
17(1):98433.
PMID: 39817135
Background: Gallbladder cancer (GBC) is the most common and aggressive subtype of biliary tract cancer (BTC) and has a poor prognosis. A newly developed regimen of gemcitabine, cisplatin, and durvalumab...
3.
Feng X, Feng G, Tao J, Ao Y, Wu X, Qi S, et al.
Comb Chem High Throughput Screen
. 2024 Jun;
PMID: 38934277
Aim: The purpose of this study was to analyze the relationship between serum indicators and high-throughput drug screening (HDS) results, aiming to achieve specific therapy for hepatocellular carcinoma (HCC). Methods:...
4.
Wu Y, Yan Q, Yue S, Pan L, Yang D, Tao L, et al.
Int J Biol Sci
. 2024 Apr;
20(6):2219-2235.
PMID: 38617542
Nonalcoholic fatty liver disease (NAFLD) is one of the common causes of chronic liver disease in the world. The problem of NAFLD had become increasingly prominent. However, its pathogenesis is...
5.
Feng G, Feng X, Tao J, Ao Y, Wu X, Qi S, et al.
J Clin Exp Hepatol
. 2024 Feb;
14(3):101337.
PMID: 38298754
Background: The magnitude of potential benefits that hypothermic oxygenated perfusion (HOPE) may provide for liver transplantation (LT) patients compared to static cold storage (SCS) remains uncertain. In this systematic review...
6.
Feng X, Feng G, Tao J, Ao Y, Wu X, Qi S, et al.
J Cancer Res Clin Oncol
. 2023 Jun;
149(12):10505-10518.
PMID: 37284841
Background: Hepatocellular carcinoma (HCC) has a high recurrence rate even after radical surgery. Postoperative adjuvant transhepatic arterial chemoembolization (PA-TACE), postoperative adjuvant hepatic arterial infusion chemotherapy (PA-HAIC), postoperative adjuvant radiotherapy (PA-RT),...
7.
Shi Z, Duan Y, Cui F, Wu Z, Li M, Song P, et al.
J Exp Clin Cancer Res
. 2023 May;
42(1):133.
PMID: 37231509
Background: Efforts to precisely assess tumor-specific T-cell immune responses still face major challenges, and the potential molecular mechanisms mediating hepatocellular carcinoma (HCC) microenvironment imbalance after incomplete radiofrequency ablation (iRFA) are...
8.
Yin K, Li M, Liao R, Shi Z, Qiu J, Lan X, et al.
J Gastrointest Oncol
. 2023 May;
14(2):932-942.
PMID: 37201094
Background: The combined immunotargeting therapy of hepatocellular carcinoma (HCC) have brought remarkable results. There are still some drawbacks to the application of the immune-modified Response Evaluation Criteria in Solid Tumors...
9.
Feng G, Shi Z, Zhao Y, Chen K, Tao J, Wei X, et al.
Front Surg
. 2023 Jan;
9:1072451.
PMID: 36684128
Aim: To evaluate the feasibility of the preoperative neutrophil-to-lymphocyte ratio (NLR) as an index to guide postoperative adjuvant transcatheter arterial chemoembolization (PA-TACE) in patients with liver cancer. Methods: We recruited...
10.
Feng G, Cheng Y, Chen K, Shi Z
Can J Gastroenterol Hepatol
. 2022 Feb;
2022:5969716.
PMID: 35127582
Aim: This study analyzed the correlation between immunohistochemical markers in hepatocellular carcinoma cells and the results of high-throughput drug sensitivity screening, to provide a reference for individualized drug treatment in...